METHOD

This protocol of systematic review was reported following Preferred reporting Items for Systematic
Review and Meta-Analyses Protocol (PRISMA-P) guidelines. 24 
Eligibility criteria: participants, interventions, comparisons and outcomes
Type of studies
Only randomized clinical trials will be included. Other types of studies such as observational studies, cohort studies, case-control studies and laboratory studies will be excluded.
Type of participants
This review will include RCTs involving immunocompromised adult patients with acute respiratory failure. The immunocompromised patients include patients with hematological malignancy, solid cancer, AIDS or who receives corticosteroid or cytotoxic therapy, or have gone through solid organ or stem cell transplantation. ARF was defined as respiratory rate >30 breaths/min and respiratory distress symptoms, PaO2 <60 mm Hg on room air or need for invasive or noninvasive MV. 16 RCTs with a subgroup of participants who meet the criteria above will also be included, on the condition that the data of outcome for this subgroup is available. It should be noted that RCTs will be included as long as more than 85% of the involved participants meet the eligibility criteria, even if the outcomes of these eligible participants are unavailable.
Type of intervention
The intervention group refers to patients treated with NIV, which includes two main modes: continuous positive airways pressure (CPAP) and bi-level positive airway pressure (BiPAP).
The control group refers to patients treated with oxygen therapy. High-flow nasal oxygen (HFNO) therapy is a relatively new method of oxygen therapy, that provides positive pressure which makes it different from standard oxygen therapy. 25 Therefore, this review will not include the trials where HFNO was applied.
We will include RCTs which directly compare NIV with oxygen therapy as the first oxygenation strategy for acute respiratory failure, regardless of whether the other oxygenation method was applied later.
Type of outcome measures
▸ Primary outcome (1)Mortality: hospital mortality, ICU mortality and mortality at the last time available, in case that mortalities of all included studies were not measured at the same time period.
(2) Incidence of tracheal intubation.
▸ Secondary outcome (1) Length of ICU stay.
(2) Length of hospital stay. The eligible RCT should include at least one of the primary outcomes listed above. of language or publication status will be applied. The filter for clinical trials will be used for each database. The following keywords were used in the database searching: immunosuppression, hematological malignancy, cancer, transplantation, corticosteroid, cytotoxic, AIDS, non-invasive ventilation, acute respiratory failure. The detailed search strategy can be seen in Supplement 1 and 2.
Search strategy for identification of studies
Searching other resources
The references of relevant studies and review articles will be sought for potential information missing in database search. Conference proceedings and grey literature will be checked. The experts in the field will be contacted to identify published and unpublished trials. We will also access www.controlledtrials.com and clinicaltrials.gov. for ongoing and unpublished studies, and the conductors or authors will be contacted for further information.
Screening of studies
All the relevant results identified by the search strategy will be screened by two reviewers (Dr. Z.L. and Dr. T.W.) independently. The first step of screening will be performed on titles and abstracts in sequence respectively, during which the irrelevant studies will be excluded according to the eligibility criteria. Then full texts of the studies that haven't been excluded will be downloaded and screened.
Reasons of exclusion will be documented and classified. Any disagreements between the reviewers will be solved through discussion and consensus. The third author (Dr. Y.L.) will be consulted if a consensus cannot be reached.
Data extraction and management
Two reviewers (Dr. Z.L. and Dr. T.W.) will independently extract all the data in the included studies.
We will use a standard form to extract the following data:
1. Characteristics of the study: design, setting, method of randomization, allocation concealment, blinding, and dropouts. 4. Outcome: primary outcomes and secondary outcomes listed above.
We will contact the authors for the missing data or data of subgroup that are unavailable from the text. The consistency of data will be ensured by these two reviewers.
Assessment of risk of bias
For the included articles, the risk of bias will be assessed by two reviewers(Dr. Y.Y. and Dr. L.Z.)
independently, using the Cochrane Collaboration criteria 26 which includes random sequence generation, allocation concealment, blinding of participants and outcome assessment, incomplete outcome data, and selective outcome reporting. Each criterion will be explicitly judged and classified as 'low risk', 'high risk', or 'unclear risk'. The author will be contacted for supplemental information if details for assessment reported in the text are considered inadequate. The risk will be rated as 'unclear' if no further information is obtained. The result of assessment of each study will be summarized in a chart.
Overall risk of bias for each study will be defined as 'low' if risk of all bias components are ranked as 'low', or 'moderate' if at least one component is ranked 'unclear' with no component ranked as 'high', or 'high' if one or more component is ranked as having a 'high' risk of bias. 
Data analyses and assessment of heterogeneity
Measures of treatment effect
The statistical analyses will be performed using RevMan 5.3 analyses software of the Cochrane Collaboration. Continuous data such as length of ICU stay and length of hospital stay will be presented as mean differences(MD) with 95% confidence intervals (95% CIs). Dichotomous data such as the number of intubation and death will be presented as risk ratios (RR) with 95% CIs. When the rate rather than the numbers are reported, we will calculate the numbers based on the data provided.
Dealing with missing data Missing data will be dealt with following the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions. Corresponding authors will be contacted for further information.
If the missing data cannot be obtained, we will specify the assumptions of the methods used to cope with missing data according to the reason of loss (i.e. random dropout or poor outcome). We will perform sensitivity analyses to evaluate how sensitive results are to the changes in the assumptions that are made. In the Discussion section of the review, we will analyze the potential impact the missing data may have on the findings of the review.
Assessment of heterogeneity
Before any outcome is pooled, we will assess the impact of heterogeneity using χ2 test and I 2 statistic
[classified as low (< 40%), moderate (40-60%) or high (> 60%)]. I 2 values greater than 60% will be considered as having substantial heterogeneity. If substantial heterogeneity is present, we will investigate the potential source of heterogeneity by conducting exploratory analyses.
Assessment of reporting biases
Protocols of included trials will be searched using the databases mentioned above. We will contact the authors to obtain a full data set claimed in the protocol and reasons for the non-reporting of certain outcomes. Publication bias will be assessed by visual analysis of the funnel plot if the number of included studies is equal to or greater than 10.
Subgroup analysis and investigation of heterogeneity Subgroup analysis will be used to explore potential sources of heterogeneity. Possible sources of heterogeneity are:
1. severity of acute respiratory failure before randomization indicated by oxygenation index, SOFA, SAPS II and APACHE II as the baseline characteristics of included patients, 2. different causes of immunosuppression.
3. different causes of acute respiratory failure.
types of NIV(CPAP or BiPAP).
Sensitivity analysis will be carried out to assess the effect of excluding the studies with high overall risk of bias or the studies in which immunocompromised patients with ARF are a subgroup other than the overall participants.
Assessment of pooled effect estimates
For the pooled assessment of treatment effect, the Mantel-Haenszel method will be used for fixed effects estimation and the DerSimonian and Laird method for random effects estimation. The random effects model was preferred if heterogeneity of treatment effects was present; otherwise a fixed effect model would be used. P values < 0.05 will be considered statistically significant. Where data aggregation is not possible due to substantial heterogeneity, the results will be presented in tables and discussed afterwards. The quality of evidence contributing to pooled effect estimates will be evaluated following the principle of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. 27 According to GRADE system, the starting point of quality of each evidence from RCT is considered to be high, and will be downgraded with the presence of study limitations, imprecision, inconsistency, indirectness or publication bias.
Finally, all the findings will be summarized in a table using the GRADE principles.
DISCUSSION
The benefit of NIV among immunocompromised patients with ARF is unclear. The recommendation of the use of NIV in those patients has been challenged by the different results of the RCTs conducted in recent years. This systematic review and meta-analysis will synthesize evidences from all the available RCTs on the efficacy of NIV and oxygen therapy as the first oxygenation strategy on adult immunocompromised patients with ARF. The evidence would be useful for clinicians regarding the use of NIV or oxygen therapy in those patients. We have noticed that severity of patients in the M Wermke's study is lower than those in Antonelli's and Hilbert's studies, which indicates that NIV might be more appropriate among severe patients, especially patients in ICU. The expected result is likely to be obtained by performing subgroup analysis. In the worst case where no conclusion could be reached, the finding of this meta-analysis could still provide guidance for the RCTs in the future to find out the characteristics of patients who will benefit from NIV. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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ABSTRACT Background
The number of immunocompromised patients has increased in recent years. Acute respiratory failure is a common complication leading to ICU admission and high mortality among such patients. The use of non-invasive ventilation(NIV) or oxygen therapy among these patients remains controversial, according to the inconsistent results of several randomized clinical trials(RCTs). This meta-analysis aims to evaluate whether NIV or oxygen therapy is the more appropriate initial oxygenation strategy for the immunocompromised patients with acute respiratory failure.
Method
We will search all the RCTs that compared the efficacy of NIV and oxygen therapy on immunocompromised adult patients with acute respiratory failure on the major databases (Cochrane Library, MEDLINE, EMBASE, Web of science etc.), conference proceedings and grey literature.
Eligible RCTs will be included in accordance with the pre-specified eligibility criteria. The risk of bias will be assessed using the Cochrane Collaboration criteria and the quality of evidence will be assessed with the GRADE system. Data will be extracted with a standardized form and analyzed using RevMan 5.3 analyses software. Heterogeneity will be assessed using I2 statistic and the source of which will be investigated. Publication bias will be identified with the funnel plot.
Discussion:
The finding of this meta-analysis will provide evidence for the use of NIV or oxygen therapy as the initial oxygenation strategy among adult immunocompromised patients with ARF.
Strengths and limitations of this study
□There is no existing meta-analysis on the use of non-invasive ventilation among immunocompromised patients with acute respiratory failure.
□This meta-analysis includes only randomized clinical trials and will thus provide the highest quality of evidence for clinical practice.
□Subgroup analysis based on different levels of severity might support the use of NIV in more severe patients.
□The number of included studies is likely to be small. 
BACKGROUND
Description of the problem
Numerous factors such as the epidemic of AIDS, 1 improved survival rates of active malignancies, 2 3 innovative advances in organ transplantation, 4 better outcomes of allogeneic hematopoietic cell transplantations 5 and the more common application of immunosuppressive therapy have contributed to an increasing number of immunocompromised patients. These patients are more vulnerable to infection due to their inadequate immune response to foreign antigens. 6 Some life-threatening complications can lead to requirement of ICU admission for these patients, among which acute respiratory failure(ARF) is the most common with particularly high mortality. 7 ARF is a relatively sudden onset of dysfunction of the respiratory system, and the most common causes among immunocompromised patients are immunosuppression-related infection, [8] [9] [10] disease-specific infiltration, 11 chemotherapy-associated organ toxicity 12 and idiopathic pneumonia syndrome associated with GVHD. 13 For severe ARF patients, invasive ventilation is required in order to support alveolar ventilation; however, such intervention also contributes to high mortality due to the risk of ventilator-associated pneumonia. 14 Therefore, the strategy of delivering oxygen is of great importance for improvement of oxygenation, which may lead to reduction of intubation rate and mortality.
Description of the intervention
The percentage of usage of non-invasive ventilation(NIV) has increased from 29% in the year of 1997 to 42% in 2011 among patients with ARF 15 . The benefits NIV may bring are associated not only with the degree of inspiratory workload spared by the positive airway pressure provided, but also with the invasive-ventilation-associated complications that are prevented by NIV. [16] [17] [18] However, the failure of NIV was identified as an independent risk factor for ICU mortality, which occurred in half of the critically ill hematologic patients. 19 Oxygen therapy, conducted via either nasal cannula, venturi mask or reservoir mask, is the basic technique used in patients with acute lung injury. Patients might benefit from oxygen therapy for less discomfort or intolerance compared with NIV.
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Why is it important to do this review?
The use of NIV was recommended for patients with acute respiratory failure in the setting of immunosuppression weak(Grade 2B) , 21 based on Antonelli's and Hilbert's randomized clinical trials(RCTs) published in 2000 and 2001, 22 23 respectively. Findings of these two studies showed that NIV was associated with reduced intubation rate and mortality in immunocompromised patients with ARF. However, findings to the contrary can be found in the publications of Wermke et al. 24 and
Lemiale et al. 25 Both of their studies showed that NIV was not associated with lowered intubation rate or mortality compared with oxygen therapy. No solid conclusion could be drawn based on the data currently available according to the reviews published in recent years, except that NIV should be applied with great caution in this group of patients. 26 27 Since the application of NIV in immunocompromised patients with ARF remains controversial, a systematic review and meta-analysis that summarizes all the available RCTs is called for to provide guidance for the management of this group of patients. To our knowledge, no meta-analysis about this topic has yet been published.
The aim of this study is to determine the efficacy of NIV in comparison with oxygen therapy as the initial oxygenation strategy on the immunocompromised patients with ARF, with respect to mortality, intubation rate and hospital length of stay and also to explore the patient selection strategy for the initial oxygenation strategy. Furthermore, the proposed systematic review will provide evidence for the use of NIV in subgroups of patients with different levels of disease severity, cause of immunosuppression and cause of ARF etc. 19 RCTs with a subgroup of participants who meet the criteria above will also be included, on the condition that the data of outcome for this subgroup is available. It should be noted that RCTs will be included if more than 85% of the involved participants meet the eligibility criteria, even if the outcomes of these eligible participants are unavailable.
Type of intervention
The control group refers to patients treated with oxygen therapy. High-flow nasal oxygen(HFNO) therapy is a relatively new method of oxygen therapy that differentiates itself from oxygen therapy by providing positive pressure; 29 Patients who have been treated with HFNO are therefore excluded from this study. As for the reports where mixed usage of HFNO and oxygen were adopted, the trial will be included if the data of sole oxygen therapy can be retrieved.We will include RCTs which directly compare NIV with oxygen therapy as the initial oxygenation strategy for acute respiratory failure, regardless of whether the other oxygenation method was applied later.
Type of outcome measures ▸ Primary outcome (1)Mortality: hospital mortality, ICU mortality and mortality at the last time available, in case that mortalities of all included studies were not measured at the same time period.
▸ Secondary outcome
(1) Incidence of tracheal intubation.
(2) Length of ICU stay. Eligible RCTs should include at least one of the primary outcomes listed above. Searching other resources
Search strategy for identification of studies
The references of relevant studies and review articles will be sought for potential information missing in database search. Conference proceedings and grey literature will be checked. The experts in the field will be contacted to identify published and unpublished trials. We will also access www.controlledtrials.com and clinicaltrials.gov. for ongoing and unpublished studies, and the conductors or authors will be contacted for further information if necessary.
Screening of studies
All results identified by the search strategy will be screened by two reviewers (Dr. Z.L. and Dr. T.W.)
independently. Initial screening will be performed on titles and abstracts respectively, where irrelevant studies will be excluded according to the eligibility criteria; full texts of the remaining studies will subsequently be downloaded and screened. Reasons of exclusion will be documented and classified.
Any disagreements between the reviewers will be solved through discussion, and the third author (Dr.
Y.L.) will be consulted if consensus cannot be reached.
Data extraction and management
Two reviewers (Dr. Z.L. and Dr. T.W.) will independently extract all the data in the included studies. A standard form will be used in extracting the following data:
Authors will be contacted for the missing data or subgroup data that are unavailable from the text.
The consistency of data will be ensured by these two reviewers.
Assessment of risk of bias
For the included articles, the risk of bias will be assessed by two reviewers (Dr. Y.Y. and Dr. L.Z.)
independently, using the Cochrane Collaboration criteria 30 which includes random sequence generation, allocation concealment, blinding of participants and outcome assessment, incomplete outcome data, and selective outcome reporting. Each criterion will be explicitly judged and classified as 'low risk', 'high risk', or 'unclear risk'. Authors will be contacted for supplemental information if details for assessment reported in the text are considered inadequate. The risk will be rated as 'unclear' if no further information is obtained. The result of assessment of each study will be summarized in a chart.
Overall risk of bias for each study will be defined as 'low' if risk of all bias components is ranked as 'low', or 'moderate' if at least one component is ranked 'unclear' with no component ranked as 'high', or 'high' if one or more component is ranked as having a 'high' risk of bias. 
Data analyses and assessment of heterogeneity
Measures of treatment effect
The statistical analyses will be performed using RevMan 5.3 analyses software of the Cochrane Collaboration. Continuous data such as length of ICU stay and length of hospital stay will be presented as mean differences (MD) with 95% confidence intervals (95% CIs). Dichotomous data such as the number of intubation and death will be presented as risk ratios (RR) with 95% CIs. When the rates rather than the numbers are reported, we will calculate the numbers based on the data provided.
If the missing data cannot be obtained, we will specify the assumptions of the methods used to cope with missing data according to the cause of data loss (i.e. random dropout or poor outcome). We will perform sensitivity analyses to evaluate how sensitive results are to the changes in the assumptions that are made. In the Discussion section of the review, we will analyze the potential impact the missing data may have on the findings of the review.
Assessment of heterogeneity
Assessment of reporting biases
Protocols of included trials will be searched using the databases mentioned above. We will contact the authors to obtain complete data of the protocols' envisioned outcomes as well as reasons for the non-reporting of certain outcomes. Publication bias will be assessed by visual analysis of the funnel plot if the number of included studies is equal to or greater than 10.
1. severity of acute respiratory failure before randomization indicated by oxygenation index, SOFA, SAPS II and APACHE II as the baseline characteristics of included patients, 2. different causes of immunosuppression, i.e HIV or non-HIV 3. different causes of acute respiratory failure.
types of NIV (CPAP or BiPAP).
Sensitivity analysis will be carried out to assess the effect of exclusion of the studies with high overall risk of bias or the studies in which immunocompromised patients with ARF are a subgroup of the overall participants.
Assessment of pooled effect estimates
As to the pooled assessment of treatment effect, the Mantel-Haenszel method will be used for fixed effects estimation and the DerSimonian and Laird method for random effects estimation. The random effects model was preferred if heterogeneity of treatment effects was present; otherwise a fixed effect model would be used. P values < 0.05 will be considered statistically significant. Results will be presented in tables and discussed afterwards where data aggregation is not possible due to substantial heterogeneity.
The quality of evidence contributing to pooled effect estimates will be evaluated following the principle of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) 31 According to GRADE system, quality of each evidence from RCT is considered to be high, and will be downgraded with the presence of study limitations, imprecision, inconsistency, indirectness or publication bias.
Finally, all the findings will be summarized in a table following the GRADE principles.
DISCUSSION
The benefit of NIV among immunocompromised patients with ARF is unclear. The recommendation of the use of NIV in those patients has been challenged by the different results of the RCTs conducted in recent years. This systematic review and meta-analysis will synthesize evidences from all the available RCTs, which would be useful for clinicians regarding the use of NIV or oxygen therapy in those patients. Besides, subgroup analysis will be performed to find out more specific indications for clinical decision making.
Patients who have been treated with HFNO will not be included in our studies, since HFNO is distinctively different from oxygen therapy in terms of equipment, cost and tolerance. HFNO requires more advanced equipment, thus it's not as popularized as standard oxygen therapy especially in developing countries such as China. Besides, the effect of HFNO is different from traditional oxygen therapy. Maggiore SM's study showed that HFNO results in fewer oxygen desaturations, lower reintubation rate and less discomfort compared to oxygen therapy after exubation. 32 And in Frat's RCT conducted among patients with ARF, HFNO resulted in reduced mortality compared with standard oxygen therapy or NIV. 33 Therefore, exclusion should be made so that HFNO would not become a confounding factor when we compare NIV with oxygen therapy.
HIV patients is a specific group, thus will be analyzed in subgroup analysis. A systematic review conducted by our team showed that non-invasive ventilation had great advantage over invasive ventilation for HIV patients, and this advantage is less obvious among non-HIV patients. 34 Furthermore, recent studies showed a higher mortality rate of Pneumocystis pneumonia infection in non-HIV patients in comparison with HIV patients. 35 36 Therefore, we propose a hypothesis that the effect of NIV is different between HIV and non-HIV patients, which will be examined by subgroup analysis in this meta-analysis.
The overall purpose of this study is to determine whether NIV is better than oxygen therapy as the initial oxygenation strategy in adult immunocompromised patients with ARF. We will also explore the patient selection strategy for the initial oxygenation strategy, with respect to severity, cause of immunosuppression and cause of ARF. The finding of this meta-analysis could also provide guidance for the RCTs in the future to find out the characteristics of patients who might benefit from NIV. This meta-analysis aims to evaluate whether NIV or oxygen therapy is the more appropriate initial oxygenation strategy for the immunocompromised patients with acute respiratory failure.
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Method
We will search all the RCTs that compared the efficacy of NIV and oxygen therapy on immunocompromised adult patients with acute hypoxemic respiratory failure on the major databases (Cochrane Library, MEDLINE, EMBASE, Web of science etc.), conference proceedings and grey literature. Eligible RCTs will be included in accordance with the pre-specified eligibility criteria. The risk of bias will be assessed using the Cochrane Collaboration criteria and the quality of evidence will be assessed with the GRADE system. Data will be extracted with a standardized form and analyzed using RevMan 5.3 analyses software. Heterogeneity will be assessed using I2 statistic and the source of which will be investigated. Publication bias will be identified with the funnel plot.
Ethics and dissemination
Ethical approval is not required since it is not carried out in humans. The systematic review will be published in peer-reviewed journals and disseminated extensively through conferences.
Strengths and limitations of this study
□There is no existing meta-analysis on the use of non-invasive ventilation among immunocompromised patients with acute hypoxemic respiratory failure.
□The number of included studies is likely to be small. Numerous factors such as the epidemic of AIDS, 1 improved survival rates of active malignancies, 2 3 innovative advances in organ transplantation, 4 better outcomes of allogeneic hematopoietic cell transplantations 5 and the more common application of immunosuppressive therapy have contributed to an increasing number of immunocompromised patients. These patients are more vulnerable to infection due to their inadequate immune response to foreign antigens. 6 Some life-threatening complications can lead to requirement of ICU admission for these patients, among which acute respiratory failure(ARF) is the most common with particularly high mortality. 7 ARF is a relatively sudden onset of dysfunction of the respiratory system, and the most common causes among immunocompromised patients are immunosuppression-related infection, [8] [9] [10] disease-specific infiltration, 11 chemotherapy-associated organ toxicity 12 and idiopathic pneumonia syndrome associated with GVHD. 13 For severe ARF patients, invasive ventilation is required in order to support alveolar ventilation; however, such intervention also contributes to high mortality due to the risk of ventilator-associated pneumonia. 14 Therefore, the strategy of delivering oxygen is of great importance for improvement of oxygenation, which may lead to reduction of intubation rate and mortality.
Description of the intervention
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Why is it important to do this review?
The use of NIV was recommended for patients with acute hypoxemic respiratory failure in the setting of immunosuppression weak(Grade 2B) , 21 based on Antonelli's and Hilbert's randomized clinical trials(RCTs) published in 2000 and 2001, 22 23 respectively. Findings of these two studies showed that NIV was associated with reduced intubation rate and mortality in immunocompromised patients with acute hypoxemic respiratory failure. However, findings to the contrary can be found in the publications of Wermke et al. 24 and Lemiale et al. 25 Both of their studies showed that NIV was not associated with lowered intubation rate or mortality compared with oxygen therapy. No solid conclusion could be drawn based on the data currently available according to the reviews published in recent years, except that NIV should be applied with great caution in this group of patients. 26 27 Since the application of NIV in immunocompromised patients with acute hypoxemic respiratory failure remains controversial, a systematic review and meta-analysis that summarizes all the available RCTs is called for to provide guidance for the management of this group of patients. To our knowledge, no meta-analysis about this topic has yet been published.
The aim of this study is to determine the efficacy of NIV in comparison with oxygen therapy as the initial oxygenation strategy on the immunocompromised patients with acute hypoxemic respiratory failure, with respect to mortality, intubation rate and hospital length of stay and also to explore the patient selection strategy for the initial oxygenation strategy. Furthermore, the proposed systematic review will provide evidence for the use of NIV in subgroups of patients with different levels of 
METHOD
This protocol of systematic review was reported following Preferred Reporting Items for Systematic
Review and Meta-Analyses Protocol (PRISMA-P) guidelines.
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Eligibility criteria: participants, interventions, comparisons and outcomes
Type of studies
Only RCTs will be included. Other types of studies such as observational studies, cohort studies, case-control studies and laboratory studies will be excluded. All included studies have to comply with international ethic rules.
Type of participants
This review will include RCTs involving immunocompromised adult patients with acute respiratory failure. The immunocompromised patients include patients with hematological malignancy, solid cancer, AIDS or those receiving corticosteroid or cytotoxic therapy, or those having gone through solid organ or stem cell transplantation. Acute hypoxemic respiratory failure is defined as respiratory rate >30 breaths/min, PaO2 <60 mm Hg on room air or labored breathing, and a partial pressure of arterial carbon dioxide (PaCO2) not higher than 45 mmHg. 19 RCTs with a subgroup of participants who meet the criteria above will also be included, on the condition that the data of outcome for this subgroup is available. It should be noted that RCTs will be included if more than 85% of the involved participants meet the eligibility criteria, even if the outcomes of these eligible participants are unavailable.
Type of intervention
The control group refers to patients treated with oxygen therapy. High-flow nasal oxygen(HFNO) therapy is a relatively new method of oxygen therapy that differentiates itself from oxygen therapy by providing positive pressure. 29 Patients who have been treated with HFNO are therefore excluded from this study. As for the reports where mixed usage of HFNO and oxygen were adopted, the trial will be included if the data of sole oxygen therapy can be retrieved. We will include RCTs which directly compare NIV with oxygen therapy as the initial oxygenation strategy for acute respiratory failure, regardless of whether the other oxygenation method was applied later. Eligible RCTs should include at least one of the primary outcomes listed above. Searching other resources
Search strategy for identification of studies
Screening of studies
Data extraction and management
Assessment of risk of bias
Overall risk of bias for each study will be defined as 'low' if risk of all bias components is ranked as 'low', or 'moderate' if at least one component is ranked 'unclear' with no component ranked as 'high', 
Data analyses and assessment of heterogeneity
Measures of treatment effect
Assessment of heterogeneity
Assessment of reporting biases
types of NIV (CPAP or BiPAP).
Assessment of pooled effect estimates
The quality of evidence contributing to pooled effect estimates will be evaluated following the principle of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. 31 According to GRADE system, quality of each evidence from RCT is considered to be high, and will be downgraded with the presence of study limitations, imprecision, inconsistency, indirectness or publication bias.
DISCUSSION
The benefit of NIV among immunocompromised patients with acute hypoxemic respiratory failure is unclear. The recommendation of the use of NIV in those patients has been challenged by the different results of the RCTs conducted in recent years. This systematic review and meta-analysis will synthesize evidences from all the available RCTs, which would be useful for clinicians regarding the use of NIV or oxygen therapy in those patients. Besides, subgroup analysis will be performed to find out more specific indications for clinical decision making.
Patients who have been treated with HFNO will not be included in our studies, since HFNO is distinctively different from oxygen therapy in terms of equipment, cost and tolerance. HFNO requires more advanced equipment, thus it's not as popularized as standard oxygen therapy especially in developing countries such as China. Besides, the effect of HFNO is different from traditional oxygen therapy. Maggiore SM's study showed that HFNO results in fewer oxygen desaturations, lower reintubation rate and less discomfort compared to oxygen therapy after exubation. 32 And in Frat's RCT conducted among patients with acute hypoxemic respiratory failure, HFNO resulted in reduced mortality compared with standard oxygen therapy or NIV. 33 Therefore, exclusion should be made so that HFNO would not become a confounding factor when we compare NIV with oxygen therapy.
The overall purpose of this study is to determine whether NIV is better than oxygen therapy as the initial oxygenation strategy in adult immunocompromised patients with acute hypoxemic respiratory failure. We will also explore the patient selection strategy for the initial oxygenation strategy, with respect to severity, cause of immunosuppression and cause of ARF. The finding of this meta-analysis could also provide guidance for the RCTs in the future to find out the characteristics of patients who might benefit from NIV. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHODS
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review Page 4, Line 9
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage Page 4, Line 53
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